Book a Test

Finding more

with multi-cancer early detection

Performance supported by large clinical studies

The Galleri test’s performance is supported by rigorous clinical studies with more than 20,000 participants representing diverse populations.3 – 5

Treating cancer starts with knowing you have it

Finding cancer early is important to improve treatment outcomes and survival.1

The vast majority of cancers show no symptoms until later stages, when treatment options may be limited.2 Today, many cancers are found too late, when outcomes are often deadly.3

Request the Galleri test

The process begins by requesting the test from a
healthcare provider.
Discover the Galleri Test

Sign up for more information
about the Galleri test

  1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data. Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin. “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
  2. Cancer Facts and Figures 2022 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf
  3. Siegel RL, et al. Cancer Statistics, 2022. CA Cancer J Clin. 2021;71(1):7 – 33.
  4. For US population ages 50 – 79. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years). Source: Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf. Data on file GA-2021 – 0065.
  5. USPSTF Cancer Screening Recommendations Grade A, B, C.
  6. Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol.2021;32(9):1167 – 1177. doi: 10.1016/j.annonc.2021.05.806.
  7. Amin MB, et al. (Eds). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017
  8. Schrag D, McDonnall CH, Naduld L, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Ann Oncol. 2022;33(suppl_7; abstr 9030). 10.1016/annonc/annonc1061 Presentation at European Society of Medical Oncology (ESMO) Congress September 9 – 13, 2022; Paris, France.